ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • Diagnostic Tests and connective tissue diseases
  • Diagnostic Tests and fibromyalgia
  • Diagnostic Tests and nervous system lupus
  • Diagnostic Tests and rheumatoid arthritis (RA)
  • Diagnostic Tests and Sjogren's syndrome
  • diet
  • diet and rheumatoid arthritis (RA)
  • diet and risk
  • dietary protein intake
  • dietary supplements
  • dietary supplements and epidemiologic methods
  • Dietary supplements and osteoporosis
  • Dietary supplements and rheumatoid arthritis
  • differential diagnosis
  • differential diagnosis and familial Mediterranean fever
  • Differential diagnosis and gout
  • differential diagnosis and immune response
  • differential diagnosis and psoriatic arthritis
  • differential diagnosis and rheumatoid arthritis (RA)
  • differential diagnosis and spondylarthritis
  • differentiation
  • differentiation and chronic inflammation
  • differentiation and Treg
  • Diffuse idiopathic skeletal hyperostosis (DISH)
  • diffuse idiopathic skeletal hyperostosis (DISH) and genetics
  • Diffuse idiopathic skeletal hyperostosis (DISH) and gout
  • diffuse idiopathic skeletal hyperostosis (DISH) and morbidity and mortality
  • digital
  • digital technologies
  • digital technologies and patient outcomes
  • digital ulcers
  • Digital X-ray Radiogrammetry (DXR)
  • Digital X-ray Radiogrammetry (DXR) and Early Rheumatoid Arthritis
  • Dipping and inflammatory markers
  • DIRA and anti-TNF therapy
  • direct and Biologics
  • direct effect and indirect effect
  • Disability
  • Disability and education
  • Disability and fibromyalgia
  • Disability and gout
  • disability and grip strength
  • disability and HAQ
  • disability and longitudinal studies
  • Disability and menopause
  • disability and morbidity and mortality
  • Disability and musculoskeletal disorders
  • disability and osteoarthritis
  • disability and primary care
  • disability and quality of life
  • disability and rheumatoid arthritis
  • Disability and rheumatoid arthritis (RA)
  • disability and scleroderma
  • disability and vasculitis
  • disability and work
  • Disaster planning
  • discoid lupus and innate immunity
  • discoid lupus erythematosus
  • discontinuation
  • Discordance
  • discrete choice experiment
  • diseae activity
  • Disease Activity
  • Disease Activity and activity score
  • disease activity and adoption
  • Disease Activity and adult-onset Still's disease
  • Disease Activity and ankylosing spondylitis (AS)
  • Disease Activity and atherosclerosis
  • Disease Activity and axial spondyloarthritis
  • Disease Activity and Biologics
  • Disease Activity and biomarkers
  • Disease Activity and body mass index
  • Disease Activity and chemokines
  • Disease Activity and chronic disease care
  • Disease Activity and clinical trials
  • Disease Activity and comorbidity
  • Disease Activity and corticosteroids
  • Disease Activity and cutaneous lupus
  • Disease Activity and diagnostic imaging
  • Disease Activity and DMARDs
  • Disease Activity and flare
  • Disease Activity and functional status
  • Disease Activity and gout
  • Disease Activity and histopathologic
  • Disease Activity and inflammation
  • Disease Activity and interferons
  • Disease Activity and interleukins (IL)
  • Disease Activity and joints
  • Disease Activity and juvenile dermatomyositis
  • Disease Activity and juvenile idiopathic arthritis (JIA)
  • Disease Activity and large vessel vasculitis
  • Disease Activity and longitudinal studies
  • Disease Activity and lupus nephritis
  • Disease Activity and methotrexate (MTX)
  • Disease Activity and obesity
  • Disease Activity and outcome measures
  • Disease Activity and outcomes
  • Disease Activity and pain
  • Disease Activity and patient engagement
  • Disease Activity and patient outcomes
  • Disease Activity and patient-reported outcome measures
  • Disease Activity and psoriatic arthritis
  • Disease Activity and quality of life
  • Disease Activity and race/ethnicity
  • Disease Activity and radiography
  • Disease Activity and remission
  • Disease Activity and rheumatic disease
  • Disease Activity and rheumatoid arthritis
  • Disease Activity and rheumatoid arthritis (RA)
  • Disease Activity and rheumatologic disease
  • Disease Activity and self-management
  • Disease Activity and Sjogren's syndrome
  • Disease Activity and SLE
  • Disease Activity and spondylarthritis
  • Disease Activity and systemic lupus erythematosus (SLE)
  • Disease Activity and T-Regulatory Cells
  • Disease Activity and Takayasu.s arteritis
  • Disease Activity and ultrasonography
  • disease burden and climate
  • Disease domain
  • Disease duration
  • disease management
  • Disease Sub-phenotyping
  • Disease Sub-phenotyping and prognostic factors
  • Disease susceptibility
  • disease susceptibility and informatics
  • disease susceptibility and rheumatoid arthritis (RA)
  • disease susceptibility and toll-like receptors
  • Disease-modifying antirheumatic drugs
  • Disease-Modifying Antirheumatic Drugs (Dmards)
  • disease-modifying antirheumatic drugs and anti-CCP antibodies
  • disease-modifying antirheumatic drugs and Biologics
  • disease-modifying antirheumatic drugs and intima medial thickness
  • disease-modifying antirheumatic drugs and methotrexate (MTX)
  • disease-modifying antirheumatic drugs and orthopedics
  • disease-modifying antirheumatic drugs and outcomes
  • disease-modifying antirheumatic drugs and psoriatic arthritis
  • disease-modifying antirheumatic drugs and registry
  • disease-modifying antirheumatic drugs and rheumatoid arthritis
  • disease-modifying antirheumatic drugs and rheumatoid arthritis (RA)
  • disease-modifying antirheumatic drugs and safety
  • Disparities
  • distance and pediatric rheumatology
  • diversity and Sjogren's syndrome
  • DMARD-free remission and Disease Activity
  • DMARDs
  • DMARDs and access to care
  • DMARDs and azathioprine
  • DMARDs and cardiovascular disease
  • DMARDs and claims
  • DMARDs and clinical trials
  • DMARDs and combination therapies
  • DMARDs and cytokines
  • DMARDs and diabetes mellitus
  • DMARDs and Disease Activity
  • DMARDs and Early Rheumatoid Arthritis
  • DMARDs and economics
  • DMARDs and health care cost
  • DMARDs and hepatitis
  • DMARDs and IL-17
  • DMARDs and inflammation
  • DMARDs and Intervention
  • DMARDs and Janus kinase (JAK)
  • DMARDs and methotrexate (MTX)
  • DMARDs and obesity
  • DMARDs and outcome measures
  • DMARDs and outcomes
  • DMARDs and patient assistance
  • DMARDs and patient outcomes
  • DMARDs and patient questionnaires
  • DMARDs and patient-reported outcome measures
  • DMARDs and pregnancy
  • DMARDs and qualitative
  • DMARDs and rheumatoid arthritis
  • DMARDs and rheumatoid arthritis (RA)
  • DMARDs and seronegative spondyloarthropathy
  • DMARDs and systemic lupus erythematosus (SLE)
  • DMARDs and tofacitinib
  • DMARDs and treatment
  • DMARDs and tuberculosis
  • DMARDs and tumor necrosis factor (TNF)
  • DMOAD
  • DMOAD and joint protection
  • DMOAD and osteoarthritis
  • DNA
  • DNA and Genetic Biomarkers
  • DNA and NET
  • DNA degradation
  • DNA Methylation
  • DNA Methylation and polyangiitis
  • DNA Methylation and rheumatoid arthritis (RA)
  • DNA sensing
  • DOCK8
  • DOCK8 and anti-dsDNA
  • doctor-patient relationship
  • doctor-patient relationship and A3 Adenosine receptor
  • doctor-patient relationship and patient outcomes
  • doctor-patient relationship and rheumatoid arthritis (RA)
  • documentation
  • dopamine agonists
  • First |
  • « Previous Page
  • 13
  • 14
  • 15
  • 16
  • 17
  • [18]
  • 19
  • 20
  • 21
  • 22
  • 23
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology